An insulin analog FiAsp with the ability to reduce postprandial blood glucose more quickly reduces the time difference between the response of endogenous and exogenous insulin and brings diabetes to a healthy human being. Patients can more easily correct postprandial hyperglycemia, which accounts for a significant proportion of total hyperglycemia, expressed as glycated hemoglobin.
At the same time, the risk of microvascular and macrovascular complications is reduced. The new ultra-short FiAsp analog improved the safety of postrandial blood glucose in randomized trials in patients with type 1 and type 2 diabetes, both in subcutaneous injection and insulin pumps.